Invisible: ADA_News

News From DiabetesMine™ D-Data ExChange

The DiabetesMine™ D-Data ExChange is a biannual event where diabetes advocates, pharma leaders, developers, clinicians, designers, and all other groups interested in diabetes tech for diabetes manag...

Dash, Tidepool Loop, Horizon: the Future of Omnipod

The Omnipod Dash is now widely available, and two hybrid closed loops, Omnipod Horizon and DASH + Tidepool are expected in the second half of 2020.

One on One With Insulet CEO Shacey Petrovic

Insulet CEO Shacey Petrovic spoke with Beyond Type 1 about her personal connection to T1D, the importance of access, the future of Omnipod and more.

Film Review: A Touch of Sugar

A Touch of Sugar may be the title of a documentary about diabetes narrated by Oscar-winning actress Viola Davis, but it actually provides a touch of hope – hope that we can collectively solve the di...

Nutritional Therapy for Adults with Diabetes or Prediabetes: ADA Consensus

Today we know that there is no single approach or nutritional treatment for people with diabetes (any type) or prediabetes

Diabetes Care in Hospitals: An Update

The American Diabetes Association included in its guidelines and overall consensus of 2019, a review and update of intrahospital management of diabetes

New Data Shows FreeStyle Libre Lowers HbA1c in People with T2D

On June 8, Abbott released new data showing the impact of the FreeStyle Libre System on those living with Type 2 diabetes. Research showed that usage significantly reduced hemoglobin A1c (HbA1c) level...

Challenging the Importance of Hypoglycemia in Type 2 Diabetes

A debate between two distinguished professors from the University of Edinburgh and Washington University in St. Louis about the seriousness of hypoglycemia in Type 2 diabetes. Their thoughts just may ...

Results from the PIONEER Program Trials: The First Oral GLP-1 Receptor

The results of the first GLP-1 receptor show it's chances of increasing the risk of cardiovascular events in people with Type 2 diabetes.

RISE Clinical Trial: Slowing the Progression of Type 2 Diabetes

The RISE clinical trial revealed the function of beta-cell function in adults with type 2 diabetes or with impaired glucose tolerance (IGT).